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Abstract  
The melanocortin receptors (MCRs) and their accessory proteins (MRAPs) are involved 
in regulation of a diverse range of endocrine pathways.  Genetic variants of these 
components result in phenotypic variation and disease.  The MC1R is expressed in skin 
and variants in the MC1R gene are associated with ginger hair colour. The MC2R 
mediates the action of ACTH in the adrenal gland to stimulate glucocorticoid production 
and MC2R mutations result in familial glucocorticoid deficiency (FGD). MC3R and 
MC4R are involved in metabolic regulation and their gene variants are associated with 
severe pediatric obesity, whereas the function of MC5R remains to be fully elucidated. 
MRAPs have been shown to modulate the function of MCRs and genetic variants in 
MRAPs are associated with diseases including FGD type 2 and potentially early onset 
obesity. This review provides an insight into recent advances in MCRs and MRAPs 
physiology, focusing on the disorders associated with their dysfunction. 
Key words melanocortin, melanocortin receptors, accessory proteins, MRAP, MRAP2, 
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The Melanocortin system  
Melanocortins are a diverse group of peptides that regulate distinct physiological 
functions. They are the products of the pro-opiomelanocortin precursor peptide 
(POMC), which is predominantly produced in humans by the corticotroph cells of the 
anterior pituitary[1]. POMC can also be produced at a number of extra-pituitary sites, 
most notably the arcuate nucleus of the hypothalamus and the nucleus of the solitary 
tract of the brainstem[2]. After synthesis, POMC is proteolytically processed by 
subtilisin-like enzymes known as prohormone convertases (PC), into a number of 
peptide hormones with distinct functions (reviewed in [3] [4] [5] Fig 1). Prohormone 
convertase 1 (PC1) cleaves POMC to produce pro-γ−MSH, ACTH and β-lipotropin, all of 
which can be processed further by PC2 resulting in α−,β−, γ−MSH, β−endorphin and the 
corticotropin-like intermediate peptide (CLIP) [6](Fig 1A). The three MSH peptides are 
all closely related (Fig 1B) and contain a central Histidine-Phenylalanine-Arginine-
Tryptophan core tetrapeptide, which is essential for receptor binding and activation (Fig 
1).  They act as ligands for a subfamily of G-protein coupled receptors called 
melanocortin receptors (MCRs).  
There are five melanocortin receptors described, which play diverse physiological 
roles[7]. MC1R regulates skin pigmentation[8], MC2R – the ACTH receptor [7]- is a vital 
component of the hypothalamo-pituitary-adrenal axis, whilst MC3R and MC4R have a 
crucial role in energy homeostasis[9], [10].  MC5R appears to be involved in exocrine 
function[11]; however, there could be other processes in which this receptor may have a 
role[12]–[15]. MCR1, 3, 4 and 5 all bind all melanocortin peptides with varying affinities 
depending on the receptor type, whereas the MC2R exclusively binds ACTH[7],[16].   
 
Apart from these agonist peptides, MCRs have specific naturally-occurring antagonists 
in the form of agouti [17],[18]and agouti-related protein (AgRP) [9], Agouti is expressed 
in hair follicular epithelial cells, from which it is secreted to suppress melanin expression 
by adjacent follicular melanocytes[17],[19]. AgRP is expressed in the adrenal cortex and 
in the hypothalamus of the brain where it antagonizes the action of α−MSH [9].  
The function of melanocortin receptors can be modulated by two related small single 
transmembrane domain proteins called Melanocortin 2 Receptor Accessory Proteins, or 
MRAPs[20],[21]. In vitro studies show that MRAP1 and MRAP2 physically interact with 
all MCRs, modulate their function and, in the case of the MC2R, trafficking to the 
plasma membrane from the endoplasmic reticulum (ER)[20], [21]. MRAP1 is 
predominantly expressed in the adrenal cortex[20], whereas MRAP2 is primarily 
expressed in the central nervous system[21]–[23].  Expression of MC2R in cells lacking 
MRAP1 – i.e. most cells of non-adrenal origin, results in retention of MC2R in the ER 
and unresponsiveness of such cells to ACTH[20],[24], [25].  
There are genetic defects reported in several of the components of the melanocortin 
system resulting in a diverse range of disorders.  These include mutations in MCRs and 
MRAP, which lead to distinct hereditary diseases. 
	 4 
Dysfunction of the Melanocortin 1 Receptor 
In addition to expression in the central nervous system and pituitary, the POMC gene 
can also be induced in both keratinocytes and melanocytes following ultra-violet (UV) 
exposure, leading to the secretion of melanocortins in a p53 dependent manner [26]–
[28]. Melanocortins, mostly α-MSH and ACTH, then act as agonists for MC1R, which is 
highly expressed in melanocytes[8]. MC1R-mediated signaling in these cells is a major 
determinant for the amount and type of melanin pigments synthesized by melanocytes, 
regulating both basal pigmentation and the UV induced tanning response[29],[30]. In 
addition, MC1R stimulation has been shown to activate the DNA damage repair and cell 
survival pathways[31]. 
The MC1R gene is highly polymorphic and many of the loss-of-function variants are 
associated with the “red hair colour” phenotype [8], [32](Fig 2). Individuals with a 
dysfunctional MC1R usually have decreased eumelanin synthesis leading to fair skin 
and an increased sensitivity to UV[33]–[35]. 
Many disruptive variants of the MC1R are associated with an increased risk of 
melanoma (Fig 2) presumably in part as a result of impaired UV DNA damage repair 
and increased apoptosis[36].  Recent work suggests that the presence of a single 
disruptive MC1R variant (known as an ‘R’ allele) is associated with a 42% increased risk 
of UV induced C>T nucleotide changes[37].  Individuals carrying a single R allele may 
not necessarily express the red hair, pale skin and freckle phenotype that is typical of 
those with two R alleles.  Consequently a single disruptive MC1R allele may be 
associated with a 66% increased risk of melanoma development as shown in both 
candidate gene association studies and in genome-wide association[38]–[40]. 
The function of the MC1R may be modulated in vitro by MRAPs in a manner similar to 
their interaction with other MCRs[21]. However, it is unclear and probably unlikely that 
MRAPs regulate MC1R function in vivo as they are not significantly expressed in skin.  
Patients with MRAP deficiency (see below) develop hyperpigmentation due to 
overstimulation of MC1R by excessive ACTH[20], which suggests that MRAP1 is 
probably not essential for MC1R function. Patients with variants in MRAP2 have not 
been reported to develop abnormal pigmentation[22].  Additionally, studies in murine 
models so far have shown little evidence for the critical role of MRAPs in MC1R function 
in vivo. In mice the effects of MC1R deregulation can be easily seen; for example, the 
lethal yellow (Agouti; Ay) mutation in mice, which leads to overexpression of the MCRs 
antagonist Agouti, results in a yellow coat colour due to diminished basal MC1R activity 
[41], [42]. Mrap1 or 2 deficient mice do not show any changes in their coat colour when 
compared to the wild type .   
 
Dysfunction of the Melanocortin 2 Receptor 
The MC2R is highly expressed in the adrenal cortex and is essential in mediating the 
action of ACTH[7], and hence it is a vital component of hypothalamic-pituitary-adrenal 
(HPA) axis, which controls circadian and stress-induced secretion of glucocorticoids 
	 5 
(reviewed in [43]). The axis is regulated by a number of distinct brain circuits that act on 
parvocellular neurons in the paraventricular nucleus of the hypothalamus (PVH)[44], 
(reviewed in [45]). In response these neurons secrete corticotropin-releasing hormone 
(CRH) and arginine vasopressin (AVP) into the hypophyseal portal circulation, which 
then triggers ACTH production by the pituitary[45]. ACTH is then released into the 
circulation to exert its function predominantly in the adrenal cortex. Although MC2R is 
expressed in all zones of the human adrenal cortex, MC2R plays an essential 
physiological role in the zona fasciculata to stimulate glucocorticoid production[7]. 
Glucocorticoids negatively feedback to regulate the release of CRH and AVP at the 
hypothalamus and ACTH at the pituitary, providing tight regulation of cortisol 
synthesis[45]. 
Inactivating defects of the MC2R predictably result in abrogation of ACTH stimulation in 
the adrenal cortex[46].  This is a potentially lethal autosomal recessive disorder known 
by several names including familial glucocorticoid deficiency (FGD), isolated 
glucocorticoid deficiency and hereditary unresponsiveness to ACTH [47] (OMIM 
♯202200).   Loss-of-function mutations in the MC2R gene comprise approximately 25% 
of all cases of FGD and this genetic cause is known as FGD type 1 [48](Fig 2a).  
Clinically FGD type 1 is characterized by partial or complete cortisol deficiency which is 
usually present from birth, although it may not be recognized for several months or even 
years[46].  Consequently, the presenting features range from severe circulatory 
collapse and hypoglycaemia leading to convulsions in the neonate at one extreme and 
to malaise with increased susceptibility to infection in childhood at the other 
extreme[47].  There is typically a very marked compensatory rise in plasma ACTH, 
which will usually result in increased cutaneous pigmentation as a result of ACTH action 
on the MC1R[47], [49].  Occasionally it is this pigmentation that will lead to the initial 
clinical contact.  An unusual case in which a patient had an inactivating mutation of both 
the MC2R and the MC1R with no excessive pigmentation in the face of highly elevated 
ACTH confirms this explanation for the cutaneous manifestation[49]. 
Typically, FGD is characterized by normal levels of mineralcorticoids, although 
occasionally some disturbance of renin or aldosterone measurements may be observed 
[50].  Sex steroids are not disturbed, but partial or complete deficiency of both 
androstenedione and DHEAS are frequently observed in childhood leading to an absent 
adrenarche [51] and clearly demonstrating the requirement for ACTH in this 
physiological process. 
A variable phenotype in FGD type 1 is tall stature and/or advanced bone age [52], [53]. 
Not all patients even with the same MC2R mutation exhibit these features and the 
length of time before glucocorticoids were replaced and ACTH levels were unopposed 
may provide a closer correlation with height. Growth hormone levels and adrenal 
androgens are typically within the reference range in such children, and the mechanism 
for this phenomenon is unknown[52], [53]. Possible explanations include excessive 
stimulation of MC1R in cartilaginous growth plates or stimulation of estradiol synthesis 
by excessive ACTH levels[54]. Alternatively, the anabolic properties of growth hormone 
unopposed by cortisol may result in this increase in height.  
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Adrenal histology from two deceased FGD patients demonstrated disorganization of the 
zona glomerulosa and almost complete absence of the zona fasciculata and reticularis 
[47]. Inevitably these adrenals were removed from very sick children with an unknown 
molecular pathogenesis and at least some exposure to glucocorticoid, and thus they 
may not be a true reflection of the typical FGD type 1 adrenal gland.  However a mouse 
model of Mc2r deficiency[55] shows that the mutant animals also develop severe 
adrenal gland pathology with a grossly dysmorphic adrenal cortex; however, there are 
some phenotypic differences from humans in that Mc2r null mice have low levels of 
mineralcorticoids and catecholamines. As with humans, Mc2r null mice exhibit profound 
neonatal hypoglycemia resulting in high mortality levels during first days of life and this 
phenotype matches the FGD presentation in patients[46], [55]. In this case the 
immediate diagnosis and treatment are essential and should include hypoglycemia 
management and lifetime glucocorticoid replacement . 
The majority of mutations in MC2R found in FGD type 1 are missense mutations, and 
homozygous (or compound heterozygous) nonsense mutations are very rare (Fig 3).  
This may in part be because the coding region of the MC2R is contained within a single 
exon, and hence splicing mutations cannot occur, but it may also be that homozygous 
nonsense mutations result in a more severe phenotype with reduced survival.  We 
demonstrated that most missense mutations result in the retention of the receptor in the 
endoplasmic reticulum, presumably because they are misfolded[56]. Less frequently 
mutations affect residues in the MC2R known to be important for binding to ACTH 
(D103N, D107N, H170L) or downstream signal transduction (R128C)[56], [57].  
Constitutively activating mutations of the MC2R are extremely rare and currently there is 
only one such mutation, F278C, described in homozygous form in a patient with cyclical 
Cushing’s syndrome[58]. Functional studies suggest this variant exhibits impaired 
desensitization and consequently enhanced basal activity.   
 
MRAP1 
Genetic studies of FGD patients with an intact MC2R identified a number of damaging 
variants in the C21orf61 gene, which would result in a truncation or complete absence 
of the protein product with then unknown function[20]. Expression analysis 
demonstrated that this gene was predominantly expressed in the adrenal cortex with 
higher levels in the zona fasciculata. Additionally MRAP1 is present in adipose tissue 
and found in several other tissues at low levels[59]. In vitro studies showed that this 
protein was able to interact with MC2R and was the adrenal specific factor required for 
the transport of the receptor from the ER to the plasma membrane[20],[21], [24],[60], 
[61]. Thus, the gene was named Melanocortin 2 Receptor Accessory Protein 1 
(MRAP1) and it is now known that its mutations cause approximately 20% of all FGD 
cases[62], [63]. There have been at least 8 different mutations reported to date and this 
form of FGD is termed type II (Fig 3). Individuals present with classic severe FGD 
usually earlier than FGD type I patients [53]. Consequently, surviving patients are 
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usually exposed to glucocorticoid replacement at an earlier stage, and the tall stature 
observed in FGD type I patients is not seen [53]. 
MRAP contains a single transmembrane domain, but no N-terminal signal sequence.  It 
is highly evolutionally conserved in the N-terminal and transmembrane regions.  Sebag 
et al[64] initially showed that MRAP1 existed as an antiparallel transmembrane 
homodimer, a form that is currently unique in eukaryotic biology (although other 
examples may not have been sought). This finding has been independently supported 
by other work using bioluminescence resonance energy transfer, which showed that 
MRAP1 homodimer forms a stable complex with MC2R in the ER and at the plasma 
membrane[65]. Human MRAP1 has two isoforms produced by alternative splicing – 
MRAP1α (19kDa protein) and MRAP1β (14kDa), which is shorter at the C-terminus. It is 
unclear whether there is a significant functional difference between these isoforms, 
although it has been suggested that MRAP1α is mostly localized to the ER whereas 
MRAP1β functions at the plasma membrane and may regulate the receptor’s 
internalization rate, facilitating MC2R plasma membrane expression[66]. It is 
hypothesized that the C-terminus of MRAP1 may regulate the affinity of MC2R to ACTH 
but this needs be elucidated further[67]. MRAP1 has been shown to form complexes 
with other melanocortin receptors and can modulate their function in vitro [21]. However, 
it is presently unclear whether MRAP1 has a function outside the regulation of MC2R in 
the adrenal gland in vivo.  
 
The Melanocortin system in the regulation of energy balance 
The melanocortin system in the brain regulates one of the most important mechanisms 
of central metabolic regulation and mostly acts in response to leptin, a hormone 
secreted by adipose tissue in proportion to adipose mass[68],[69]. High leptin levels 
potently suppress appetite and increase energy expenditure by activating sympathetic 
pathways in the brain[70]. Initially, leptin signals to its receptors expressed in the 
neurons of the arcuate nucleus of the hypothalamus (ARH) and modulates the 
expression of POMC and AgRP as well as altering the neuronal firing rate[71]. These 
neurons then project further to secondary hypothalamic sites such as the 
paraventricular nucleus (PVH), which mostly controls feeding behaviour, and the 
dorsomedial hypothalamus (DMH), which regulates the level of sympathetic activity by 
projecting further to the brainstem[72].  These mechanisms have been reviewed in 
detail elsewhere and will not be recapitulated here ([69],[73],[72]). A crucial intermediate 
of this signaling pathway is α-MSH (and probably also β-MSH in humans), which is 
secreted by POMC neurons in the ARH upon activation by leptin and which acts on 
centrally expressed MC3R, MC4R and the accessory protein MRAP2[74]. Genetic 
variants in these genes are associated with metabolic imbalance and obesity. 
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Dysfunction of the Melanocortin 4 Receptor  
Nearly 20 years ago genetic studies identified heterozygous mutations in the MC4R 
gene in two cohorts of severely obese children [75] and adults[76]. To date there are 
around 160 loss-of-function mutations in MC4R described that cause obesity and it is 
suggested that defects in this gene are responsible for 2% to 6% of all cases[77] (Fig 4). 
The majority of the mutations are heterozygous and thus this disorder is dominant. A 
few homozygous mutations in the MC4R have also been reported, which associate with 
a more severe phenotype compared to heterozygous patients[77]. The reported genetic 
defects in MC4R are predominantly missense (around one hundred and twenty), eight 
mutations are nonsense, fourteen are small deletions, five are small insertions and two 
– small insertions/deletions (Fig 4). There are polymorphisms V103I and I251L that are 
considered receptor activating and such individuals are lean with a low BMI, 
demonstrating the opposite phenotype[78], [79]. Furthermore, MC4R has been 
implicated in anorectic conditions including cachexia[80], which is observed in patients 
with chronic diseases such as renal failure, heart failure, rheumatoid arthritis and 
cancer. MC4R antagonism has been shown to alleviate cachexia in several cancer 
models as well as in uremia [80]–[82], revealing a promising strategy to tackle cachexia.  
Patients with obesity caused by loss-of-function MC4R mutations present in childhood 
with severe obesity and increased appetite, which may moderate with age[77],[83]. The 
majority of the patients are euglycemic, although they exhibit hyperinsulinemia when 
compared to age- and BMI- matched obese patients with intact MC4R[77]. Tall stature, 
increased lean mass, high bone density and bone mineral content are typical for MC4R 
patients, which differentiates them from other forms of obesity[77], [83]. Endocrine 
function in MC4R patients appears to be normal with glucocorticoids and thyroid 
hormones usually within normal range and circulating leptin levels appropriate for fat 
mass[77]. Despite some evidence coming from mouse studies that MC4R can be 
involved in reproductive physiology (reviewed in [84]), this function is intact in the 
patients reported[77],[85].  
Studies using genetically modified mice provide an insight into the key structures and 
pathways involved in MC4R regulation. Mc4r null mice replicate human disease and 
develop severe early onset obesity due to hyperphagia and reduced energy expenditure 
combined with increased linear growth, high bone density and elevated cholesterol 
levels[86],[87]–[90]. Gene expression studies in both humans and mice demonstrated 
that MC4R is rather widely expressed in the central nervous system with higher levels of 
the MC4R transcript found in the PVH. MC4R activation in the PVH by α-MSH triggers 
potent satiety signals and suppresses feeding behavior in response to leptin[91],[90]. 
MC4R is also expressed in the brainstem predominantly in nucleus tractus solitarius 
and dorsal motor nucleus of the vagus nerve[90]. MC4R activation at these sites can 
increase sympathetic output to stimulate energy expenditure, which includes higher 
oxygen consumption and increased thermogenesis[90].  
Importantly, sympathetic activation by MC4R in the brainstem also raises blood 
pressure[92],[93]. Clinical studies report that the prevalence of hypertension in patients 
with MC4R-associated obesity is lower than in control subjects with a similar degree of 
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obesity and those with normal BMI[94]. Such aspect of the function of MC4R may limit 
the use of MC4R agonism as a therapeutic approach for obesity treatment. Indeed, 
hypertension was one of the adverse side effects of such therapy during trials of the first 
generation of MC4R agonists and resulted not only in suppression of food intake and 
induction of weight loss, but also in a significant increase in blood pressure and heart 
rate in rodents, primates, and in humans[94].  
Recently novel compounds have been developed, such as setmelanotide [95],[96]. This 
synthetic cyclic peptide agonist binds to human MC4R with high affinity and has been 
shown to reduce food intake, body weight and restore insulin sensitivity in diet-induced 
obese mice, rats, dogs, and monkeys[95]. Importantly, drug-related changes in heart 
rate and blood pressure have not been observed in a series of setmelanotide phase 
1b/2a or experimental studies in obese individuals[97]. In a 28-day Phase 1b clinical 
trial, setmelanotide led to weight loss in obese MC4R variant carriers[97]. Interestingly, 
patients with defects in the POMC gene, have shown significantly more weight loss with 
setmelanotide than MC4R deficient patients or obese controls[97]. Further studies are 
needed before the compound will be considered for wider obesity management. 
Moreover, there is evidence arising from studies in rodents that MC4R can be 
implicated in regulation of several physiological processes outside the metabolic and 
cardiovascular function such as the reward pathways and memory consolidation[98], 
[99]. Therefore, due to the complexity of MC4R-regulated pathways, adverse side 
effects other than hypertension are possible and the use of MC4R agonists should be 
validated further.   
MRAP2 and its role in obesity 
MRAP2 is the only identified paralogue of MRAP1, sharing 39% identity	 in the N-
terminal and transmembrane domains, and the two proteins have been shown to form 
heterodimers[21]. Numerous in vitro studies demonstrated that MRAP2 binds to and 
regulates melanocortin receptors in a manner highly similar to MRAP1[21], [22], [67], 
[100]. In vivo evidence indicates that the function of MRAP2 is non-redundant, as it 
does not compensate for the lack of MRAP1 function in patents with type II FGD[101]. 
Recently, four rare heterozygous variants in MRAP2 gene were identified in patients 
with early onset obesity [22](Fig 3b). The patient carrying the most damaging E24X 
variant exhibited a severe phenotype, while two of the patients (possible damaging 
variants N88Y and R125C) were modestly obese compared to the subject with benign 
variant (L115V) who had a normal BMI[22]. These gene variants suggest that MRAP2 
could be involved in metabolic regulation. Gene expression studies show that MRAP2 is 
expressed in the central nervous system with higher levels found in the PVH, including 
the neurons that express MC4R[22], [23]. Some in vitro studies demonstrate that 
MRAP2 can enhance α-MSH signaling via MC3R and MC4R[22], indicating a potential 
molecular role for MRAP2 in the regulation of the central melanocortin system. 
To study whether MRAP2 modulates melanocortin function in vivo and to scrutinize the 
mechanisms by which MRAP2 regulates energy balance, mouse models of MRAP2 
deficiency have been utilized. The Mrap2 deficient mice develop severe early onset 
obesity and have several other phenotypic similarities with the Mc4r null model such as 
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high cholesterol levels[22],[23]. Targeted deletion of Mrap2 in the PVH results in the 
phenotype identical to full body Mrap2 gene knockout, suggesting that MRAP2 functions 
mainly in this hypothalamic nucleus[22]. Gene expression analysis of the PVH from 
Mrap2 deficient mice demonstrated down-regulation of a transcription factor, SIM1, 
which is activated by the MC4R signaling pathway and for which heterozygous gene 
variants are associated with severe early onset obesity[23]. Other genes, for which 
expression is driven by SIM1 were also down-regulated, adding more evidence in 
support of melanocortin pathway deficiency hypothesis[23].   
However, Mrap2 deficient mice do not fully recapitulate Mc4r null phenotype.  Unlike 
hyperphagic Mc4r knockout mice with markedly reduced energy expenditure, Mrap2 
deficient animals do not demonstrate detectable changes in food intake or energy 
expenditure[22], [23]. They also retain their anorexic response to a potent MC3R/MC4R 
agonist MTII, suggesting some preservation of the MC4R function[22]. Moreover, 
double Mrap2/Mc4r knockout animals have an intermediate degree of obesity between 
the solo knockouts, rather than developing a highly severe phenotype[22]. These data 
suggest that MRAP2 may be involved in the regulation of other non-melanocortin 
pathways. Recent studies demonstrated that MRAP2 may modulate the function of the 
Prokineticin Receptor-1 and -2 (PKR1, PKR2), orexin receptor (OX1R) and ghrelin 
receptor (GHSR1a) [103,104] and it has been shown that the Mrap2 knockout mice are 
hypersensitive to PKR1 stimulation[102]. Nevertheless, it is unclear how the interaction 
of MRAP2 and these other receptors occurs in vivo, as these receptors are located in 
the ARC, while MRAP2 effects on obesity appear to be localized to the PVH, and these 
additional pathways need further elucidation.   
Thus, these studies of MRAP2 function highlight the complexity of MC4R physiology 
and provide evidence for novel regulatory pathways for metabolic balance, making 
MRAP2 an intriguing target for future anti-obesity drugs; however, further studies are 
needed to gain greater insight into the MRAP2-mediated pathways. For example, the 
potential role of MRAP2 in regulation of the MC3R, which is implicated in the metabolic 
balance, needs further investigation.   
 
The role of MC3R in metabolic regulation  
Early linkage studies suggest that the MC3R locus may be involved in body weight 
regulation[105]. Subsequent it was shown that heterozygous variants in the MC3R 
coding sequence could be associated with obesity [106] (Fig 2b). For example, a 
heterozygous missense variant I183N that inactivates MC3R function has been 
identified in two individuals with obesity[107]. Other variants, such as C17A and G241A, 
have not been found to affect MC3R signaling or be associated with obesity individually; 
however, when both variants are present, an association with obesity is 
apparent[108],[109].  
There are several other lines of evidence that indicate that MC3R may have a function 
in metabolic regulation. MC3R is highly expressed in the ARH and VMH, where it 
responds to stimulation by α- and γ-MSH [110]. Extensive studies using genetically 
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modified mouse models suggest the involvement of MC3R in metabolic regulation. 
Although Mc3r null mice do not develop any significant increase in body weight, they 
show an increase in fat mass and a reduction in lean mass[111]. However, exactly 
where and how MC3Rs affects metabolic control to alter nutrient partitioning is not 
known. Interestingly, the impact of Mc3r deficiency on feeding behavior when food is 
freely available is very minor; however, responses to hypocaloric conditioning are 
compromised featuring partial insulin resistance and enhanced lipogenesis[112]–[114]. 
Apart from metabolic features, Mc3r null mice develop other phenotypes such as high 
susceptibility to salt-sensitive hypertension[115] and, due to expression of MC3R 
outside the brain, increased immune response resulting in a complex phenotype 
(reviewed in [116]). 
There is a possibility that MRAP2 could be involved in MC3R regulation of metabolic 
function. Both proteins interact and MRAPs have been shown to modulate the signaling 
of MC3R in vitro[21], [22]; however, they do not appear to be essential for either surface 
expression of the receptor or its signaling - unlike the MC2R.  MRAP2 is moderately 
expressed in the ARH[22], [102], suggesting a potential function for MRAP2 in 
regulation of MC3R. Nevertheless, it is unclear which aspect of MC3R function MRAP2 
may regulate in the ARH, as the Mrap2 deficient animals do not develop a reduction in 
lean mass and, contrary to Mc3r knock out mice, are markedly obese from an early 
age[22], [23].  
Further studies are needed to validate the significance of MC3R dysfunction in human 
obesity and to identify the exact mechanisms by which MC3Rs controls appetite 
responses and partitioning of nutrients between fat and lean tissues. While currently 
MC3R is not widely considered as a target for obesity treatment, it could be a promising 
approach to tackle the fasting response and abnormal nutrient partitioning. Furthermore, 
the potential role for MRAP2 in regulation of MC3R function should be investigated to 
explore this aspect of targeting MRAP2 for future anti-obesity therapies.   
 
MC5R function 
Genetic variants in the MC5R are not associated with any diseases and the role of 
MC5R, which has a very wide expression pattern in vivo, remains unclear. Some 
evidence for MC5R physiology comes from murine models. Initial studies demonstrated 
that MC5R function was mostly associated with exocrine regulation as Mc5r knockout 
mice exhibit severe defects in water repulsion and thermoregulation due to decreased 
production of sebaceous lipids[117]. However, recent studies implicate MC5R in 
metabolic regulation as it was found to mediate α-MSH signaling in the skeletal muscle 
to drive glucose disposal and thermogenesis[118]. There could be other roles for MC5R 
such as mediating a pheromonal signal for aggression in mice [13], [14]. Another 
research line suggests that MC5R can have a role in adrenal gland physiology to 
respond to α-MSH, which could stimulate aldosterone production, although this has yet 
to be verified[119], [120]. Additionally, MC5R is also believed to play an important part 
in embryogenesis [121], [122]and mouse embryonic stem cells express MC5R instead 
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of other MCRs[123]. Moreover, there is evidence that MC5R could be involved in the 
regulation of the immune response as in cultured B-lymphocytes where α-MSH binding 
to MC5R activates the Jak/Stat pathway that is normally activated by cytokines[124].  
MRAPs have been suggested to down-regulate both surface expression of MC5R and 
its signaling in vitro[21]. It would be interesting to investigate whether modulation of 
MC5R by MRAPs has any role in the above functions of MC5R, perhaps revealing other 
aspects of melanocortin regulation in vivo. 
 
Conclusions 
In the twenty five years since Mountjoy et al [7] first reported discovery of the 
melanocortin receptor gene family there has been an explosion of work into their roles 
in physiology and their dysfunction in human disease.  In adrenal biology the 
identification of the elusive ACTH receptor revealed a family of potentially lethal genetic 
disorders caused by defects in ACTH signaling, steroidogenesis and reactive oxygen 
damage to the gland. The little suspected role of the MC4R in appetite regulation and 
obesity has become a central focus in the attention paid to combating this contemporary 
disease process.  A series of “co-factors” for melanocortin action including the MRAPs, 
the Agouti and AGRP proteins have been exposed and continue to be the focus of 
research.  It is to be hoped that the next quarter century of melanocortin receptor 
research will lead to novel and effective treatments for metabolic and adrenal disorders. 
 
Practice points 
• FGD is a life-threatening autosomal recessive hereditary disorder that requires 
immediate diagnosis and therapy.  
• FGD is strongly suggestive of a mutation in MC2R (type I FGD) or MRAP (type II 
FGD). Patients with type II FGD may develop a more severe phenotype 
compared to type I. . 
• Mutations in MC4R should be considered in paediatric patients with severe early 
onset obesity, especially those with tall stature. Rarely such phenotypes may be 
caused by variants in MRAP2. 
• MC4R agonists are a potentially exciting approach to obesity treatment, but 
should be trialed with caution due to probable adverse effects resulting from the 
complexity of MC4R actions. 
 
Research agenda 
• The mechanisms by which the MRAPs interact with and influence melanocortin 
receptor physiology are poorly understood and elucidation of these is likely to 
reveal novel cellular mechanisms.  
	 13 
• Understanding MC4R function in metabolic and non-metabolic pathways is 
essential for prediction of potential additional phenotypes and possible adverse 
effects of MC4R agonists 
• Elucidation of MRAP2 regulated pathways maintaining the energy balance is 
needed to provide with future potential drug targets for obesity treatment 
• Further evaluation of MC3R function in metabolic regulation, the significance of 
MC3R variants in obesity and the role of MRAP2 in MC3R-regulated pathways. 
• Clarification of the function of MRAPs in regulation of MC1R function of in vivo 
• Follow-up studies are needed to investigate the role of MC5R in metabolic 
function and whether it could be modulated by MRAPs in vivo. 
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Figure Legends 
Fig. 1. A) POMC processing and main melanocortin peptides. The human POMC 
protein schematic is shown with the MSH core tetrapeptide highlighted in red. 
Prohormone convertases 1 and 2 (PC1 and PC2 cleavage sites positions are indicated. 
POMC is processed to produce adrenocorticotropic hormone (ACTH), β- and γ-
lipotropins (β-LPH, γ-LPH), α-, β- and γ- melanocyte stimulating hormone (γ-MSH), β-
endorphin (β-END) and Corticotropin-Like Intermediate Peptide (CLIP). The length of 
the peptides produced is indicated above each bar. (modified from [5]). B) Multiple 
alignment (ClustalW) of human ACTH, α-, β- and γ- MSH with identical residues 
highlighted in red with an asterisk  
Fig. 2. Genetic variants in codons of MC1R shown on a pseudosctructural plot of the 
receptor. Source – Human Gene Mutation Database (HGMD) 
Fig. 3. Mutations in MC2R and MRAP1 causing FGD. Pseudostructural plot of MC2R 
with the codons encoding amino acids of MC2R (left) or MRAP (right) depicted as 
circles. Red circles show the position of the codons affected: substitutions (missense 
mutations)- red circles; black circles highlight the position of nonsense mutations, blue – 
small deletions and green – small insertions. The mutation in MRAP1 indicated with an 
arrow results in a premature stop codon at amino acid position 32 due to the inserion 
c.106+2_3dupTA/T 
Fig 4. Variants in MC3R and MC4R associated with obesity with affected codons 
depicted as follows: red circles – missense mutations, black circles – nonsense 
mutations, blue – small deletions, green – small insertions, red/blue – the codon can be 
affected by either missense mutation or a deletion, red/green – the codon can be 
affected by either missense mutation or an insertion, black/green – a codon affected by 
either a nonsense or an insertion. 
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